Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:SGYP

Synergy Pharmaceuticals (SGYP) Stock Price, News & Analysis

Synergy Pharmaceuticals logo

About Synergy Pharmaceuticals Stock (NASDAQ:SGYP)

Advanced Chart
Remove Ads

Key Stats

Today's Range
N/A
50-Day Range
$0.01
$0.03
52-Week Range
N/A
Volume
N/A
Average Volume
6.08 million shs
Market Capitalization
$7.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. Its lead product is plecanatide, a novel uroguanylin based gastrointestinal platform that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome. The company also develops dolcanatide to treat mild-to-moderate ulcerative colitis. It has a licensing agreement with Cipher Pharmaceuticals Inc. to develop, market, distribute, and sell TRULANCE in Canada. Synergy Pharmaceuticals Inc. is headquartered in New York, New York. On December 12, 2018, Synergy Pharmaceuticals Inc. along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.

Remove Ads
Receive SGYP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Synergy Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SGYP Stock News Headlines

Jose Solorio
Nvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."
If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk’s new technology could help launch an entirely new multitrillion-dollar industry.
Synergy Pharmaceuticals Inc Unit (SGYPU)
Different resistors
Mains cables
See More Headlines

SGYP Stock Analysis - Frequently Asked Questions

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) released its earnings results on Thursday, November, 8th. The biopharmaceutical company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by $0.01. The biopharmaceutical company had revenue of $11.11 million for the quarter, compared to analyst estimates of $15.65 million.

Based on aggregate information from My MarketBeat watchlists, some other companies that Synergy Pharmaceuticals investors own include Novavax (NVAX), Immunomedics (IMMU), Progenics Pharmaceuticals (PGNX), Westmoreland Coal (WLB), ACADIA Pharmaceuticals (ACAD), Cara Therapeutics (CARA) and Inovio Pharmaceuticals (INO).

Company Calendar

Last Earnings
11/08/2018
Today
3/28/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:SGYP
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-224,330,000.00
Net Margins
-332.11%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$16.82 million
Price / Cash Flow
N/A
Book Value
($0.02) per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$7.44 million
Optionable
Optionable
Beta
4.94
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:SGYP) was last updated on 3/29/2025 by MarketBeat.com Staff
From Our Partners